ReviewDrugs2020
Isatuximab: First Approval.
Review in Drugs, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 75 citations in OpenAlex.
- Comprehensive safety evaluation of isatuximab in multiple myeloma using disproportionality analysis of FAERS and meta-analysis of randomized controlled trials.Scientific reports · 2024Pooled it
- Isatuximab: A Review in Transplant-Ineligible Newly Diagnosed Multiple Myeloma.Targeted oncology · 2026Review
- Drug-induced neutropenia: A comprehensive pharmacovigilance study of the FAERS database.Medicine · 2026Article
- Biopharmaceuticals for Cancer Treatment: An Update.Cancer medicine · 2026Review
- A rabbit anti-human CD38 antibody for eliminating daratumumab and isatuximab interference in immunohematology testing.Frontiers in immunology · 2026Article
- CD38Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Monoclonal Antibodies in Relapsed-Refractory Multiple Myeloma.Pharmaceuticals (Basel, Switzerland) · 2025Review
- CD46 and CD59 inhibitors enhance complement-dependent cytotoxicity of anti-CD38 monoclonal antibodies daratumumab and isatuximab in multiple myeloma and other B-cell malignancy cells.Cancer biology & therapy · 2024Article
- Review
- Therapeutic progress in relapsed/refractory multiple myeloma.Annals of hematology · 2024Review
- BCMA/CD47-directed universal CAR-T cells exhibit excellent antitumor activity in multiple myeloma.Journal of nanobiotechnology · 2024Article
- Epigenetic regulation of CD38/CD48 by KDM6A mediates NK cell response in multiple myeloma.Nature communications · 2024Article
- Cardiovascular adverse events associated with targeted therapies for multiple myeloma: a pharmacovigilance study.Frontiers in immunology · 2024Article
- Application of CD38 monoclonal antibody in kidney disease.Frontiers in immunology · 2024Review
- Preclinical characterization of a novel investigational monoclonal antibody CM313 with potent CD38-positive cell killing activity.Frontiers in immunology · 2024Article
- Bispecific anti-CD38/CD28 antibodies for treatment of multiple myeloma.Pharmaceutical patent analyst · 2024Review
- Immunotherapy of Multiple Myeloma: Current Status as Prologue to the Future.International journal of molecular sciences · 2023Review
- Article
- Therapeutic Targets of Monoclonal Antibodies Used in the Treatment of Cancer: Current and Emerging.Biomedicines · 2023Review
- Multi-targeted immunotherapeutics to treat B cell malignancies.Journal of controlled release : official journal of the Controlled Release Society · 2023Review
Corrections and comments
- Erratum issued
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Isatuximab (isatuximab-irfc; Sarclisa
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.